摘要
目的探究倍氯米松雾化吸入对慢性阻塞性肺疾病急性加重期患者的疗效。方法 42例慢性阻塞性肺疾病急性加重期患者,随机分为对照组与实验组,每组21例。对照组给予沙丁胺醇和异丙托溴铵雾化吸入治疗,实验组在对照组基础上联合倍氯米松雾化吸入治疗,对比两组患者血气分析指标、不良反应发生情况及症状改善所需时间。结果实验组治疗后动脉血二氧化碳分压、动脉血氧分压分别为(48.28±3.36)、(81.32±3.11)mm Hg(1 mm Hg=0.133 kPa),优于治疗前的(71.75±5.67)、(53.66±2.23)mm Hg;对照组治疗后动脉血二氧化碳分压、动脉血氧分压分别为(58.46±4.21)、(70.98±3.31)mm Hg,优于治疗前的(71.55±5.55)、(53.70±2.21)mm Hg;且实验组治疗后血气分析指标优于对照组,差异均具有统计学意义(P<0.05)。实验组咳喘、肺啰音改善所需时间及住院时间分别为(4.82±1.22)、(5.92±1.58)、(7.50±1.66)d,均短于对照组的(6.97±1.63)、(7.95±1.58)、(10.82±1.57)d;实验组不良反应总发生率为4.76%,低于对照组的28.57%,差异均具有统计学意义(P<0.05)。结论给予慢性阻塞性肺疾病急性加重期患者采用倍氯米松联合沙丁胺醇和异丙托溴铵雾化吸入治疗有利于改善血气指标与提升用药安全性,值得临床进一步推广应用。
Objective To investigate the efficacy of beclomethasone aerosol inhalation on acute exacerbation of chronic obstructive pulmonary disease. Methods A total of 42 patients with acute exacerbation of chronic obstructive pulmonary disease were randomly divided into control group and experimental group, with 21 cases in each group. The control group was treated with salbutamol and ipratropium bromide aerosol inhalation therapy, and experimental group received beclomethasone aerosol inhalation therapy on the basis of the control group. Comparison were made on blood gas analysis indicators, occurrence of adverse reactions and time required for symptom improvement between the two groups. Results After treatment, the experimental group had better arterial blood carbon dioxide partial pressure, arterial oxygen partial pressure respectively as (48.28±3.36) and (81.32±3.11) mm Hg (1 mm Hg=0.133 kPa) than (71.75±5.67) and (53.66±2.23) mm Hg before treatment. The control group had better arterial blood carbon dioxide partial pressure, arterial oxygen partial pressure respectively as (58.46±4.21) and (70.98±3.31) mm Hg than (71.55±5.55) and (53.70±2.21) mm Hg before treatment. The experimental group had better blood gas analysis index after treatment than the control group, and the difference was statistically significant (P<0.05). The experimental group had shorter time required for cough and asthma, pulmonary rales improvement and hospitalization time respectively as (4.82±1.22),(5.92±1.58) and (7.50± 1.66) d than (6.97±1.63),(7.95±1.58) and (10.82±1.57) d in the control group. The experimental group had lower total incidence of adverse reactions as 4.76% than 28.57% in the control group, and the difference was statistically significant (P<0.05). Conclusion For patients with acute exacerbation of chronic obstructive pulmonary disease, beclomethasone combined with salbutamol and ipratropium bromide aerosol inhalation treatment is conducive to improving blood gas indicators and enhancing drug safety, and it is wor
作者
周志森
朱成楼
张明
汪绪伦
黄至辉
ZHOU Zhi-sen;ZHU Cheng-lou;ZHANG Ming(Department of Critical Care Medicine,Dongguan Hengli Hospital,Dongguan 523460,China)
出处
《中国现代药物应用》
2019年第10期8-10,共3页
Chinese Journal of Modern Drug Application
关键词
倍氯米松
慢性阻塞性肺疾病
急性加重期
沙丁胺醇
血气指标
Beclomethasone
Chronic obstructive pulmonary disease
Acute exacerbation
Salbutamol
Blood gas index
